Both of your comments demonstrate why the ASX is not the right place for MSB... it is the Nasdaq.
We have had a bruising listing but it is not the beginning of the end, it's the end of the begininng.
Also biotechs are a long term investment. The last week or so shows they're not for the faint-hearted either...but we do have stage 3 CHF clinical trials so help is at hand but you must be patient in both senses!
opportunity, page-21
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |